Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress

Business Wire05-09

-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation -- SEATTLE, May 09, 2024--(BUSINESS WIRE)--Omeros Corporation (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2434018297?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mrmX1ylvhX3By6wkCJG_Rw--~B/aD0zNDI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/74c0ffbf914b56c4fcdd0e1604c5179d","is_english":true,"pubTime":"2024-05-09 20:50","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2434018297","market":"us","top_or_hot":-1,"title":"Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress","media":"Business Wire","content":"<div>\n<p>-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation --\nSEATTLE, May 09, 2024--(BUSINESS WIRE)--Omeros Corporation (...</p>\n\n<a href=\"https://finance.yahoo.com/news/omeros-corporation-announces-upcoming-presentations-125000172.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-09 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/omeros-corporation-announces-upcoming-presentations-125000172.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation --\nSEATTLE, May 09, 2024--(BUSINESS WIRE)--Omeros Corporation (...</p>\n\n<a href=\"https://finance.yahoo.com/news/omeros-corporation-announces-upcoming-presentations-125000172.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/omeros-corporation-announces-upcoming-presentations-125000172.html","article_id":"2434018297","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mrmX1ylvhX3By6wkCJG_Rw--~B/aD0zNDI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/74c0ffbf914b56c4fcdd0e1604c5179d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2434018297","pubTimestamp":1715259000,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation --. SEATTLE, May 09, 2024----Omeros Corporation  today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024 European Hematology Association  Hybrid Congress has been selected for podium presentation. The EHA Congress will be held June 13-16, 2024, in Madrid, Spain. OMS906 is Omeros’ investigational inhibitor of MASP-3 targeting the alternative pathway of complement. Two additional poster presentations directed to OMS906 will also be featured at the congress.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Omeros公司宣布即将在2024年欧洲血液学协会（EHA）混合大会上发表演讲","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMER":1},"content_text":"-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation --\nSEATTLE, May 09, 2024--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024 European Hematology Association (EHA) Hybrid Congress has been selected for podium presentation. The EHA Congress will be held June 13-16, 2024, in Madrid, Spain. OMS906 is Omeros’ investigational inhibitor of MASP-3 targeting the alternative pathway of complement. Two additional poster presentations directed to OMS906 will also be featured at the congress.\nThe abstracts for all three presentations are scheduled to be published on May 14, 2024 and will be available on the EHA website at ehaweb.org. Details of the congress presentations are found below.\nOMS906, A Novel Alternative Pathway MASP-3 Inhibitor, Improved Hematologic Parameters in PNH Patients with Suboptimal Response to Ravulizumab Treatment: Phase 2 Dose-Finding Study Interim Results (Abstract #S189)Session Name: s454 Clinical and translational in bone marrow failure syndromes and PNHDate: Saturday, June 15, 2024Podium Presentation Session Time: 4:30 p.m. CESTLocation: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall N102Presenting Author: Morag Griffin MBChB, FRCPath\nClinical Pharmacology of OMS906, a Potent Inhibitor of MASP-3 and the Alternative Pathway of Complement Activation (Abstract #P834)Date: Friday, June 14, 2024Presentation Time: 6:00 p.m. - 7:00 p.m. CESTLocation: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall 7Presenting Author: William Pullman MB BS, PhD, FRACP\nExposure-Response Modeling Using Population PK/PD Methods Reliably Predict Population and Individual Responses of Complement Mature Factor D, Hemoglobin and LDH in PNH Patients Exposed to OMS906 (Abstract #P1920)Date: Friday, June 14, 2024Location: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall 7Presenting Author: William Pullman MB BS, PhD, FRACP\nThe presentation materials associated with each abstract will be made available on Omeros’ website at www.omeros.com following the congress presentations.\nAbout OMS906\nOMS906 is an investigational humanized monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. The complement system plays a central role in inflammation and becomes activated as a result of tissue damage or microbial infection. Responsible for the conversion of pro-complement factor D to complement factor D, MASP-3 is believed to be the premier target in the alternative pathway – it has the lowest native circulating level and low relative clearance compared to the other alternative pathway proteins and, unlike C5 and C3 blockers, MASP-3 inhibition leaves intact the lytic arm of the classical pathway, important for fighting infection. Also, unlike other components of the alternative pathway, MASP-3 is believed not to be an acute phase reactant, which could provide a significant advantage to MASP-3 inhibitors, like OMS906, over other alternative pathway inhibitors. MASP-3 inhibitors are thought to have preventive and/or therapeutic effects across a broad range of diseases including paroxysmal nocturnal hemoglobinuria (PNH), hemolytic uremic syndrome (HUS), atypical HUS, traumatic brain injury, arthritis, wet age-related macular degeneration, ischemia-reperfusion injury, transplant-related complications and other immune-related disorders.\nAbout Omeros Corporation\nOmeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 multi-ascending-dose clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing toward Phase 3 clinical trials for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros’ lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder and, in addition, is being developed as a therapeutic for other addictions as well as for a major complication of treatment for movement disorders. Omeros also is advancing a broad portfolio of novel immuno-oncology programs comprised of two cellular and three molecular platforms. For more information about Omeros and its programs, visit www.omeros.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240509156472/en/\nContacts\nJennifer Cook WilliamsCook Williams Communications, Inc.Investor and Media RelationsIR@omeros.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2434018297"}